Pre-made Sacituzumab benchmark antibody ( Whole mAb ADC, anti-TACSTD2 therapeutic antibody, Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-503
Pre-Made Sacituzumab biosimilar, Whole mAb ADC, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Sacituzumab biosimilar, Whole mAb ADC, Anti-TACSTD2 Antibody: Anti-EGP-1/EGP1/GA733-1/GA7331/GP50/M1S1/TROP2 therapeutic antibody|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University|
|Conditions Approved||Breast cancer|
|Conditions Active||Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma|